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The initial step in successful islet transplantation is procurement of healthy donor islets. Given the limited number of donor
pancreata selected for islet isolation and that islets from multiple donors are typically required to obtain insulin independence,
it is critical to improve pancreas procurement rates and yield of islets for transplantation. Islets are delicate microorgans that
are susceptible to apoptosis, hypoxia, and ischemia during isolation, culture, and the peritransplant period. Once the islets are
engrafted, both prompt revascularization and protection from beta-cell death and graft rejection are key to secure long-term
survival and function. To facilitate the engraftment of more robust islets suitable for combating the challenging isolation period
and proinﬂammatory transplantation milieu, numerous approaches have been employed to prevent beta-cell dysfunction and
death including immune modulation, prevention of apoptosis and hypoxia, as well as stimulation of growth factors, angiogenesis,
and reinnervation. In addition to brieﬂy discussing islet isolation procedures, procurement rates, and islet transplantation, the
relevantliteraturepertainingtosuccessfulsuboptimalislettransplantationisreviewedtoprovideinsightintopotentialapproaches
to balance the limited supply of available donor islets.
1.Islet Transplantation
Islet transplantation is an experimental procedure available
to a limited group of type 1 diabetes patients. The procedure
was pioneered by Lacy in 1967, when he established a
collagenase-based isolation procedure to procure islets from
rat pancreata [1] .Af e wy e a r sl a t e r ,L a c ya n dc o l l e a g u e s
reported the ﬁrst successful islet transplantation in rodents
and primates [2, 3], and by the late 1980s the ﬁrst islet
transplant to obtain insulin independence in a diabetic
patient was achieved [4]. Over the next decade, optimization
of the islet isolation protocol and use of immunosuppressive
drugs with less deleterious side eﬀects became focal points
in the ﬁeld culminating with the establishment of the
Edmonton protocol in 2000 [5, 6]. The success of the
Edmonton group arose in part because of the use of freshly
isolatedisletsfrommultipledonors,xenoprotein-freeculture
conditions,andomittingtheuseofcorticosteroidstoprevent
rejection. Instead, a combination of immunosuppressive
drugs was used that targets IL-2 and hence T- and B-cell
stimulation to prevent islet allograft rejection and diminish
recurrent autoimmunity. The standard immunosuppressive
cocktail used comprises tacrolimus (a calcineurin inhibitor
that blocks IL-2 production), sirolimus (inhibitor of the
mTOR protein kinase involved in signal transduction and
lymphocyte proliferation), and anti-IL2 receptor antibodies
(diminishes IL-2 driven T-cell proliferation during the acute
rejection phase).
Obtaining glucose stability is crucial to diabetes patients
with acquisition of insulin independence being the obvious
long-termgoal.Longitudinalstudieshaveshownthat75%of
islet grafts fail within the ﬁrst two years after transplantation,
and hence patients return to exogenous insulin therapy [7].
To evaluate the success of islet transplantation, a beta score2 Journal of Transplantation
has been established as a physiological measure of beta-
cell function that simultaneously evaluates glycemic control,
endogenous insulin secretion, and diabetes therapy [8]. The
beta score has been found to be inversely proportional to the
level of panel reactivity antibodies such that a high level of
panel reactive antibodies is associated with a lower beta score
that is indicative of a decreased islet transplantation success
rate and vice versa [9]. Even in transplant recipients that
return to insulin therapy, the insulin dose required is typi-
callylowerthanthatusedbeforetransplantandtheisletgraft
ensures that the patient largely avoids the potentially life-
threatening hypoglycemic episodes associated with insulin
therapy. In conjunction with actual beta-cell loss, beta-cell
dysfunction also seems to contribute to insulin dependence
given that most transplant recipients have residual serum
C-peptide [10–12]. Data suggest that ∼50–70% of the
transplanted islet cells undergo apoptosis during isolation,
culture, and the peritransplant period [13]. Numerous
challenges remain in order to move the ﬁeld ahead: optimize
the isolation procedure to improve islet yield, purity, and
function, optimize culture conditions to improve the quality
of pretransplant material, and improve posttransplant graft
survival by ﬁne-tuning the immunosuppression regimen to
be less diabetogenic [14–16]. Due to the vicinity of the
endocrine tissue to digestive enzymes in the pancreas, fast
procurementpost-mortemisnecessary.Apartfrommechan-
ical damage during the islet isolation procedure, islets are
separated from their nourishing microenvironment and
subjected to devascularization, denervation, and hypoxia
[17]. The brief culture period after isolation may provide
the islet with a much-needed recovery period prior to
transplantationandmayalsoallowfordepletionofpassenger
leukocytes and deactivation of intracellular stress signaling
pathways to diminish allorejection [18]. Once transplanted,
islets need to revascularize and reinnervate rapidly for
survival and proper glucose sensing but at this critical
time point also face allorejection, recurrent autoimmunity,
possible amyloid deposition, and metabolic stress. Delayed
angiogenesis, immune and nonimmune mechanisms that
result in the release of cytokines, chemokines, and reactive
oxygen species and ensuing ER stress all counter successful
islet engraftment and function. The immunosuppressive
regimens in current use have known toxicity to islet cells,
with tacrolimus and sirolimus showing deleterious eﬀects on
bothductandbeta-cellgrowthandsurvivalaswellascausing
nephrotoxicity [19,20].Anadditional sideeﬀectofsirolimus
reported in female patients after transplant is the occurrence
of ovarian cysts [21]. Lifelong immune suppression increases
the susceptibility to opportunistic infections and incidence
of malignancy [22].
Non-immune mechanisms partake in islet graft failure,
evident from a proportion of islet autograft recipients
who still require insulin therapy following transplant [23–
25]. However, given that the 5-year insulin-independence
requirement for autografts is similar to the 2-year allograft
persistence rate, autografts appear to be more durable, likely
due to the lack of allo- and autoimmune rejection as well
as the lack of any potentially toxic eﬀect of immune sup-
pression [9]. Indeed a recent study demonstrated that
insulin secretion and glucose tolerance were similar in
recipients of an islet allograft and autograft only when the
allograft group received double the number of islets [24].
In addition, the contribution of a heterotopic transplant site
and ensuing alternative implant microenvironment should
not be underestimated despite the less invasive nature of
infusing islets into the portal vein compared to whole-organ
pancreas transplantation [26]. Ultimately it is of importance
to the islet transplantation ﬁeld to optimize the islet isolation
protocol as well as minimize the various destabilizing or
toxic contributors to the graft environment, since multiple
factors reduce the eﬀective number of functional islets
after transplantation. To this end several recent promising
advances have been made to optimize the ﬁeld: one study
persuﬄated the pancreas to increase oxygenation of the
tissue which elevates ATP levels during preservation [27];
another study targeted donor-speciﬁc memory T cells with a
neutralizing antibody to the adhesion molecule lymphocyte
function-associated antigen 1 in combination with a cocktail
of basiliximab and sirolimus or belatacept in order to
minimize the activity of this blockade-resistant population
of memory T cells [28].
2.Islet YieldandRecovery inMice andMen
The standard donor-to-recipient ratio for islet transplan-
tation is presently 2–4:1, in contrast to a ratio of 1:1
for whole-pancreas transplantation. This requirement of
islets from multiple donors in order to obtain insulin
independence is a major obstacle in islet transplantation
and limits the number of patients that can beneﬁt from the
procedure. In clinical islet transplantation, a large number
of islets (>900,000 islet equivalents) is required to achieve
normoglycemia [6, 10]. A human pancreas contains 0.3–
1.5 × 106 islets per pancreas of which only 30–50% can
be isolated using current islet isolation protocols [29]. It is
further estimated that only ∼65% of human islets are viable
following isolation, suggesting that there is a huge margin
for improvement [30, 31]. Indeed, successful restoration of
insulin independence following allotransplantation of islets
from a single donor per recipient has been reported in
eight diabetes patients [32]. Stringent donor and recipient
inclusion criteria, optimized islet isolation, culture, and
implantation together with a modiﬁed immunosuppressive
protocol were key factors in attaining insulin independence
from the single donor. It will be of interest to learn about
thelong-termfollow-upofthesepatients.Alternativesources
of beta-cells have been detailed in several reviews and range
from insulin-producing cells derived from adult stem cells or
other progenitors to xenografts obtained, for example, from
porcine pancreata [33–35].
The challenges that need to be overcome in clinical
islet transplantation are mimicked in murine islet trans-
plantation models, although caution must be used when
applying insight gained from animal models to patients.
In order to reduce the donor-to-recipient ratio in human
islet transplantation, lessons learned from animal models are
crucial for improving islet isolation and culture techniques,Journal of Transplantation 3
as well as the function and viability of the transplanted islets
[36]. Similar to human islet isolation, the procurement rate
of mouse islets is far from optimal. It has been estimated
that ∼2000 islets are present in a mouse pancreas with the
typical islet yield being ∼10%, or ∼200 islets per mouse [37].
The number of islets engrafted in murine islet transplants is
usually 300–500 islets resulting in a donor-to-recipient ratio
of 1.5–2.5, and of these islets ∼60% have been reported to
be lost in the peritransplant period [38]. When considered
with the ﬁnding that only 20% of the pancreas is necessary to
maintain normoglycemia following partial pancreatectomy
[39], it should be suﬃcient to transplant fewer islets and
still obtain euglycemia as long as the islets are healthy and
functional. By increasing the yield of viable islets obtained
from each pancreas, it should be possible to decrease the
donor-to-recipient ratio.
3.SuboptimalIslet Transplantation
In animal models of islet transplantation, a number of
approaches have been used to obtain euglycemia following
transplantation of a suboptimal islet mass. Strategies to
prevent apoptosis and promote immune regulation, revas-
cularization, and reinnervation in addition to providing
metabolic rest for the implanted islets can all be beneﬁ-
cial to long-term transplant outcome. Apart from direct
administration of cytoprotective agents in the peritransplant
period,vehiclesusedtoexpressthesesubstancesincludegene
therapy,porousscaﬀolds,andgelatinousmicrospheres.Gene
therapy approaches using lenti-, adeno-, or adenoassociated
viral vectors show promise as a means to modify islet
protein expression prior to transplantation. The beneﬁts and
issues associated with using gene therapy to improve islet
survival in the peritransplant period and assist long-term
engraftment as well as the risks associated with transfer to
a clinical setting have recently been reviewed [40].
3.1. Strategies to Prevent Apoptosis or Induce Immunomod-
ulation. Beta-cells are highly susceptible to apoptosis trig-
gered by a variety of mechanisms including ER stress,
reactive oxygen species, and cytokine-mediated cell death.
Readers are referred to several recent in-depth reviews
of beta-cell apoptosis [41–45]. Approaches aimed at pro-
moting anti-apoptotic and anti-inﬂammatory properties in
suboptimal islet transplantation include activation of the
inducible cytoprotective protein, heme oxygenase-1 (HO-1)
byadministrationofcobalticprotoporphyrinIXtominimize
functional impairment, and apoptosis of the transplanted
islets [46]. Alternatively, exposure to carbon monoxide, the
product of HO-1, generates cytoprotective cyclic GMP and
its dependent kinases [47]. Ex vivo gene transfer of A20, an
inhibitoroftheproinﬂammatorynuclearfactor-κBinhibitor,
has been shown to protect islets from cytokine-mediated
beta-celldeathandactivationoftheextrinsiccaspasecascade
[48]. Engraftment of a functional, suboptimal islet mass was
maintained up to six months by inhibiting the intrinsic cas-
pase cascade via treating islets before transplant with gelati-
nous microspheres containing a cell membrane-permeable
Bax-inhibiting pentapeptide [49]. This pentapeptide has
also been shown to prevent translocation of mitochon-
drial cytochrome c, which aﬀords further cytoprotection
to the islets. Our group has recently demonstrated that
overexpression of the X-linked inhibitor of apoptosis protein
(XIAP) in islets allows for a suboptimal graft of only
100 islets to normalize blood glucose levels in a syngeneic
transplant model [50]. Analysis of the islet grafts in the
immediate posttransplant period revealed fewer apoptotic
beta-cells in recipients of XIAP-expressing grafts compared
to control grafts suggesting that XIAP enhances graft success
by inhibiting beta-cell apoptosis. Blocking caspase activation
via administration of the pan-caspase inhibitor IDN-6556,
which has been used clinically to treat hepatic disorders
associated with excessive apoptosis, likewise, results in the
successful engraftment of a suboptimal islet mass [51].
3.2. Strategies to Induce Revascularization and Reinnervation.
Via an intricate network of fenestrated capillaries, islets
receive 5–10% of the pancreatic blood volume despite
comprising only 1-2% of the pancreatic mass [52]. As a con-
sequence of isolation, islets are severed from their nutritious,
normoxic environment and prompt revascularization is cru-
cial to prevent apoptosis and ensure successful islet function
after transplantation. It has been reported that levels of vas-
cular endothelial growth factor (VEGF) in transplanted islets
are markedly reduced a few days after transplantation and
that the time required for revascularization of transplanted
islets is approximately two weeks [53, 54]. Hence, several




ies been shown to fare better by transplanting islets trans-
duced with vascular endothelial growth factor (VEGF) or
the controlled release of gelatinized ﬁbroblast growth factor
(FGF). These two growth factors act to stimulate angiogene-
sis and de novo vessel formation by facilitating the diﬀeren-
tiation of endothelial cells into a vascular plexus [55–58]. A
recent study evaluated administration of liver-speciﬁc FGF-
21 in a suboptimal islet transplantation setting [59]. Apart
from stimulating angiogenesis, this growth factor is involved
in the regulation of glucose, lipid, bile acids, and phosphate
metabolism and was shown to improve the engraftment
rate of a minimal number of islets (80 islets). Yet another
study took advantage of the synergistic eﬀects of VEGF and
hepatocytic growth factor to enhance revascularization and
prevent delayed angiogenesis commonly associated with islet
transplantation [60]. An alternative approach used to stim-
ulate angiogenesis as well as prevent inﬂammation involved
cotransplantation of allogeneic islets with syngeneic adipose
tissue-derived stem cells [61]. The survival and function of
these islet grafts are enhanced likely due to increased levels of
von Willebrand-positive cells and a decreased inﬁltration of
macrophages and CD4- and CD8-positive cells.
Severing of extracellular matrix proteins during islet
isolation causes trauma to the islets, disrupts the islet-matrix
interface, and leads to anoikis. In an attempt to facilitate4 Journal of Transplantation
the regeneration of a normal islet microenvironment after
transplantation, collagen IV, ﬁbronectin, or laminin was
absorbed to porous scaﬀolds prior to seeding them with 125
islets to enhance integration of the graft [62]. Of the three
extracellular matrix proteins tested, collagen IV maximized
graft function by accelerating reversal to euglycemia as
well as improving the response rate to a glucose challenge
suggesting that integrin-mediated interaction is important
for islet survival. The authors speculate that the extracellular
matrix proteins may lead to upregulation of VEGF, which
stimulates both host and donor endothelial cells to pro-
mote vascularization. Fibroblast-populated collagen matrix
is another novel scaﬀo l du s e dt op r o m o t ei s o g r a f ts u r v i v a l
[63]. Via production of ﬁbronectin and growth factors, this
particular scaﬀold enhances islet cell viability and function
and stimulates islet cell proliferation.
Another important circuit to reestablish promptly after
transplantation is islet reinnervation. One study undertook
a neurotrophic approach by culturing islets for 48 hours
with nerve growth factor, which has been shown to play an
important regulatory role in beta-cell function and facilitate
reinnervation [64]. This approach resulted in prolonged
survival of a suboptimal, syngeneic islet graft by enhancing
beta-cell function. Given that larger islets, tend to have a
necrotic core following isolation, another study explored the
diﬀerence between small and large rat islets in a marginal
transplantation model [65]. The smaller islets (<150μm)
were superior to larger islets, and the authors speculated that
this diﬀerence was caused by the faster revascularization of
thesmallerislets.Itislikelythatsmallerisletsalsoreinnervate
faster and hence overall regain metabolic control earlier.
3.3. Additional Strategies to Minimize Number of Islets for
Transplantation. A report documented that maintaining
islets in a pelleted, compacted state prior to transplantation
is detrimental to transplant outcome and that immediate
engraftment is recommended [66]. Others have demon-
strated that treating recipients with insulin implants in
the weeks immediately before and after transplantation
to counteract hyperglycemia provides a metabolic rest for
newly engrafted islets and improves transplant outcomes
[38]. Likewise, continuous treatment with the insulinotropic
drug liraglutide, a long-acting human glucagon-like peptide
1 analog, improved glucose homeostasis in a syngeneic,
suboptimal islet transplantation model [67].
4.Perspectives
The approaches discussed in this paper focus on establishing
a nurturing microenvironment for successful engraftment
of a suboptimal islet mass and substantiates the direct link
between number and viability of islets and transplantation
outcome. It is likely that adjunct therapies or combination
methodologies are necessary to enhance long-term graft
survival by targeting several of the pathways that cause
primary graft nonfunction, partial loss of the islet graft, or
graft rejection. A synergistic approach that prevents beta-
cell apoptosis while modulating the immune response and
enhancing prompt revascularization seems promising. To
this end, proteins that inhibit cell death such as XIAP show
promise as a means to lower the donor-to-recipient ratio.
Developing alternative gene delivery vehicles that are less
toxic and immunogenic will be of importance. The impetus
for continuous optimization of the initial islet isolation and
transplantation protocol is strong. These advances hold great
promise to extend availability of islet transplantation to a
much larger group of type 1 diabetes patients.
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